# US 2025/0084089 A1 · Unique and Selective Targeting of CDK Activity in Aggressive Carcinomas

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084089 A1
- Document ID: US20250084089A1
- Status: Published application
- Kind: A1
- Application number: 18/821,262
- Filed: 2024-08-30
- Published: 2025-03-13
- Earliest claimed: 2023-09-01
- Assignees: University of Windsor
- Applicants: University of Windsor
- Inventors: John F. Trant; Lisa A. Porter; Bre-Anne Fifield; Daniel Meister; John J. Hayward; Lavleen Mader; Maria Teodora Secara
- Web page: https://patentgrep.com/patent/US20250084089A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

In a preferred embodiment, there is provided a compound having structural Formula I, II, III or IV.

## Claims

### Claim 1

A compound having structural formula I, II, III or IV or a pharmaceutically acceptable salt, hydrate, solvate, polymorph or prodrug thereof:
wherein X is O or N; L is absent or C1-C4 alkylene; R1 is an optionally substituted aryl or heteroaryl; and R2 is an optionally substituted cycloalkyl, bicycloalkyl, tricycloalkyl, cycloheteroalkyl, bicycloheteroalkyl or tricycloheteroalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is optionally substituted phenyl or thiophenyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein L is absent and R1 is phenyl substituted with one or more of —SO2NH2, —SOCH3 or —CO2H, or R1 is
wherein R is remainder of the compound.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is
wherein R is remainder of the compound.

### Claim 5 (depends on 2)

The compound of claim 2, wherein R1 is thiophenyl substituted with —SO2NH2 or L and R1 are
wherein R is remainder of the compound.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is an optionally substituted C5-C8 cycloalkyl, C8-C14 bicycloalkyl or 8- to 14-membered bicycloheteroalkyl containing one to four heteroatoms each selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R2 is optionally substituted cyclohexyl, bicyclo[4.3.0]nonyl, bicyclo[3.3.0]octyl, octahydro-1H-indolyl or octahydro-1H-cyclopenta[b]pyridinyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R2 is optionally substituted
wherein R is remainder of the compound.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R2 is optionally substituted with one or more of —NH2, —CH2NH2, —OH, —CH2OH, —CO2H,
wherein R is remainder of the compound.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R2 is
wherein
Z1 is —H or —OH;
Z2 is —H or
Z3 is —H, —NH2 or —CH2NH2;
Z4 is —H or —NH2;
Z5 is —H, —NH2 or —CO2H;
Z6 is —H, —NH2, —OH, —CH2NH2 or —CH2OH;
Z7 is —H, —NH2, —OH, —CO2H, —CH2NH2 or —CH2OH;
Z8 is —H;
Z9 is —H, —NH2 or —OH; and
R is remainder of the compound.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R2 is
wherein Z1 and Z2 are each —H; Z3 is —H, —NH2 or —CH2NH2; Z4 is —H or —NH2; Z5 is —H, —NH2 or —CO2H; Z6 is —H, —NH2, —OH, —CH2NH2 or —CH2OH; Z7 is —H, —NH2 or —OH; Z8 is —H; Z9 is —H or —NH2; and R is remainder of the compound.

### Claim 12 (depends on 10)

The compound of claim 10, wherein R2 is
wherein Z1 is —H or —OH; Z2 is —H or
Z3 is —H or —NH2; Z4 is —H; Z6 is —H, —CH2NH2 or —CH2OH; Z7 is —H, —OH, —NH2, —CO2H or —CH2NH2; Z8 is —H; Z9 is —H or —OH; and R is remainder of the compound.

### Claim 13 (depends on 10)

The compound of claim 10, wherein R2 is
wherein Z1, Z2, Z4 to Z6, Z8 and Z9 are each —H; Z7 is —H or NH2; and R is remainder of the compound.

### Claim 14 (depends on 6)

The compound of claim 6, wherein R2 is
wherein Z10 is —H or —OH; Z11 is —H or —CH2NH2; and R is remainder of the compound.

### Claim 15 (depends on 6)

The compound of claim 6, wherein R2 is
wherein Z12 is —H or —OH;
R13 is —H or —CH2NH2; and R is remainder of the compound.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R2 is

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is one of the compounds listed in Tables 1 and 2, excluding flavopiridol, dinaciclib, purvalanol A and NU6102.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is coupled to a fluorescent, biotin or proteolysis-targeting chimera (PROTAC) moiety, optionally wherein the fluorescent, biotin or PROTAC moiety is coupled to RI.

### Claim 19 (depends on 1)

A method for treating cancer, the method comprising administering to a patient the compound as defined by claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound is for binding to an active site of a complex comprising a cyclin-dependent kinase and Spy1, wherein the cyclin-dependent kinase is Cdk1 or Cdk2.

### Claim 21 (depends on 19)

The method of claim 19, wherein the cancer is a breast, brain, liver, blood, prostate, endometrial and ovarian cancer.

### Claim 22 (depends on 18)

A method for identifying, imaging or quantifying a Spy1-Cdk2 complex in a sample, the method comprising contacting the sample with the compound as defined by claim 18, wherein the compound is coupled to the fluorescent moiety at R1.

### Claim 23 (depends on 18)

A method for identifying a protein target of the compound as defined by claim 18, the method comprising contacting the compound with a sample, wherein the compound is coupled to the biotin moiety at R1.

### Claim 24 (depends on 1)

A pharmaceutical composition for treating cancer, the composition comprising the compound as defined by claim 1 and a pharmaceutically acceptable excipient.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the cancer is a breast, brain, liver, blood, prostate, endometrial and ovarian cancer.
